» Articles » PMID: 37285311

The Influence of the "cancer" Label on Perceptions and Management Decisions for Low-grade Prostate Cancer

Abstract

Background: Grade Group 1 (GG1) prostate cancer should be managed with active surveillance (AS). Global uptake of AS remains disappointingly slow and heterogeneous. Removal of cancer labels has been proposed to reduce GG1 overtreatment. We sought to determine the impact of GG1 disease terminology on individual's perceptions and decision making.

Methods: Discrete choice experiments were conducted on 3 cohorts: healthy men, canonical partners (partners), and patients with GG1 (patients). Participants reported preferences in a series of vignettes with 2 scenarios each, permuting key opinion leader-endorsed descriptors: biopsy (adenocarcinoma, acinar neoplasm, prostatic acinar neoplasm of low malignant potential [PAN-LMP], prostatic acinar neoplasm of uncertain malignant potential), disease (cancer, neoplasm, tumor, growth), management decision (treatment, AS), and recurrence risk (6%, 3%, 1%, <1%). Influence on scenario selection were estimated by conditional logit models and marginal rates of substitution. Two additional validation vignettes with scenarios portraying identical descriptors except the management options were embedded into the discrete choice experiments.

Results: Across cohorts (194 healthy men, 159 partners, and 159 patients), noncancer labels PAN-LMP or prostatic acinar neoplasm of uncertain malignant potential and neoplasm, tumor, or growth were favored over adenocarcinoma and cancer (P < .01), respectively. Switching adenocarcinoma and cancer labels to PAN-LMP and growth, respectively, increased AS choice by up to 17%: healthy men (15%, 95% confidence interval [CI] = 10% to 20%, from 76% to 91%, P < .001), partners (17%, 95% CI = 12% to 24%, from 65% to 82%, P < .001), and patients (7%, 95% CI = 4% to 12%, from 75% to 82%, P = .063). The main limitation is the theoretical nature of questions perhaps leading to less realistic choices.

Conclusions: "Cancer" labels negatively affect perceptions and decision making regarding GG1. Relabeling (ie, avoiding word "cancer") increases proclivity for AS and would likely improve public health.

Citing Articles

Impact of alternative diagnostic labels for melanoma in situ on management choices and psychological outcomes: protocol for an online randomised study.

Wu Z, Nickel B, Boroumand F, Elder D, Ferguson P, Scolyer R BMJ Open. 2025; 14(12):e089558.

PMID: 39806624 PMC: 11667480. DOI: 10.1136/bmjopen-2024-089558.


Impact of a simple informative leaflet on Brazilian doctors' attitudes towards active surveillance of thyroid microcarcinomas.

Duarte F, Faro F, Ward L, Cury A, Ferraz C, Padovani R Heliyon. 2024; 10(17):e37300.

PMID: 39296249 PMC: 11409082. DOI: 10.1016/j.heliyon.2024.e37300.


Impact of the diagnostic label for a low-risk prostate lesion: protocol for two online factorial randomised experiments.

Bullen J, Nickel B, McCaffery K, Wilt T, Smith J, Boroumand F BMJ Open. 2024; 14(8):e085947.

PMID: 39122400 PMC: 11331948. DOI: 10.1136/bmjopen-2024-085947.


Putting patients first to redefine prostate cancer classifications.

Nyame Y, Gore J, Lin D J Natl Cancer Inst. 2023; 115(11):1249-1251.

PMID: 37463855 PMC: 10637029. DOI: 10.1093/jnci/djad124.

References
1.
Eastham J, Auffenberg G, Barocas D, Chou R, Crispino T, Davis J . Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management. J Urol. 2022; 208(1):10-18. DOI: 10.1097/JU.0000000000002757. View

2.
Hamdy F, Donovan J, Athene Lane J, Mason M, Metcalfe C, Holding P . 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med. 2016; 375(15):1415-1424. DOI: 10.1056/NEJMoa1606220. View

3.
Anderson E, Gu L, Oyekunle T, De Hoedt A, Wiggins E, Gay C . Lifestyle and sociodemographic factors associated with treatment choice of clinically localized prostate cancer in an equal access healthcare system. Prostate Cancer Prostatic Dis. 2022; 25(3):593-595. DOI: 10.1038/s41391-022-00551-4. View

4.
Nickel B, Barratt A, McGeechan K, Brito J, Moynihan R, Howard K . Effect of a Change in Papillary Thyroid Cancer Terminology on Anxiety Levels and Treatment Preferences: A Randomized Crossover Trial. JAMA Otolaryngol Head Neck Surg. 2018; 144(10):867-874. PMC: 6233823. DOI: 10.1001/jamaoto.2018.1272. View

5.
Mottet N, van den Bergh R, Briers E, Van den Broeck T, Cumberbatch M, De Santis M . EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2020; 79(2):243-262. DOI: 10.1016/j.eururo.2020.09.042. View